3 results about "Colon carcinoma" patented technology

The disclosure relates to peptide conjugates specific for Epithelial cell adhesion molecule (EpCAM) and the use thereof to detect and treat epithelial cell-derived cancers such as intrahepatic cholangiocarcinoma (ICC), hepatocellular carcinoma (HCC), breast cancer, colon cancer and basal cell carcinoma of the skin. The disclosure also relates to methods to monitor the therapeutic response of treated patients by detecting expression of EpCAM.

The present invention relates to use of a PI3Kα-mutant selective inhibitor, specifically, use of compound 1, a racemate, a stereoisomer, or a pharmaceutically acceptable salt thereof, in the preparation of a drug for preventing and / or treating HR-positive / HER2-negative breast cancer, colon cancer, and head and neck cancer. The compound 1 can inhibit the growth of HR-positive / HER2-negative breast cancer cells, colon cancer cells, and head and neck squamous cell carcinoma cells, and can be used in combination with a CDK4 / 6 inhibitor or a selective ER degrading agent, having better therapeutic efficacy and good safety.

A humanized antibody specifically recognizing human CA IX, and to therapeutic and diagnostic methods utilizing this antibody is disclosed. The methods relate in particular to treatment or diagnosis of cancers selected from squamous cell carcinoma, myeloma, small-cell lung cancer, non-small cell lung cancer, glioma, hodgkin's lymphoma, non-hodgkin's lymphoma, acute myeloid leukemia, multiple myeloma, gastrointestinal (tract) cancer, renal cancer, ovarian cancer, liver cancer, lymphoblastic leukemia, lymphocytic leukemia, colorectal cancer, endometrial cancer, kidney cancer, prostate cancer, thyroid cancer, melanoma, chondrosarcoma, neuroblastoma, pancreatic cancer, glioblastoma multiforme, cervical cancer, brain cancer, stomach cancer, bladder cancer, hepatoma, breast cancer, colon carcinoma, mesothelioma, and head and neck cancer.